跳至主要内容
临床试验/CTRI/2019/03/018291
CTRI/2019/03/018291已完成3 期

Rivastigmine for Cognitive Impairment in Multiple Sclerosis : A Parallel Group Randomised Open Label study with Blinded End point Assessment

AMRITA GOTUR0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Written informed consent to participate in the trial.
  • 2. Males and Females between 18 yrs and 65 yrs of age
  • 3. Definite diagnosis of Multiple Sclerosis as defined by 2017 Revised Mc Donald Criteria
  • 4. Sufficient education to read, write and communicate comprehensibly.

排除标准

  • -Relapse in the recent 2 months
  • -Presence of systemic disease affecting cognition ( stroke, head trauma, PD),
  • -Presence of neuropsychiatric conditions affecting cognition ( major depression ),
  • -Those who refuse consent
  • -Pregnant and lactating women

研究者

发起方
AMRITA GOTUR

相似试验

A trial to study the effect of a medicine,... | 临床试验